B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma.
B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma.
复制标题
B细胞淋巴瘤2抑制剂维奈托克治疗皮肤T细胞淋巴瘤患者。
DOI：
10.1016/j.jdcr.2020.12.025
复制
发表时间：
2021-03
影响因子：
--
通讯作者：
Girardi M
中科院分区：
文献类型：
--
作者：
King ALO;Mirza FN;Lewis JM;Carlson KR;Huntington S;Foss FM;Girardi M
皮肤T细胞淋巴瘤（CTCL）是一种皮肤归巢T细胞非霍奇金淋巴瘤（NHL），在晚期可能涉及血液和淋巴结，仍然需要有效、持久的治疗方法。批准的CTCL药物的总体反应率范围为30%至50%，可用的口服药物仅限于贝沙罗汀（第三代类维生素A）和伏立诺他（组蛋白脱乙酰酶抑制剂）。1美国食品和药物管理局最近批准了口服药物venetoclax，一种B细胞淋巴瘤2（BCL-2）的选择性抑制剂，用于慢性淋巴细胞白血病，小淋巴细胞淋巴瘤和急性骨髓性淋巴瘤。2在几种白血病和NHL细胞系中，BCL-2表达与维奈托克敏感性相关。3我们最近还报道，患者来源的CTCL细胞对维奈托克表现出不同的敏感性，其中一部分显示皮摩尔范围的50%抑制浓度，并且维奈托克敏感性与基线BCL-2表达相关。4，5在此，我们介绍了一名皮肤和血液受累的CTCL患者，每天接受维奈托克治疗。
There remains a need for effective, durable therapies for cutaneous T-cell lymphoma (CTCL), a skin-homing T-cell non-Hodgkin lymphoma (NHL) that in advanced stages may involve the blood and lymph nodes. Overall response rates for approved CTCL agents range from∼ 30% to 50%, with available oral agents limited to bexarotene (a third-generation retinoid) and vorinostat (a histone deacetylase inhibitor). 1 The US Food and Drug Administration recently approved the oral agent venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), for chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid lymphoma. 2 In several leukemia and NHL cell lines, BCL-2 expression correlates with venetoclax sensitivity. 3 We also recently reported that patient-derived CTCL cells exhibited variable sensitivity to venetoclax, with a portion showing picomolar-range 50% inhibitory concentrations, and that venetoclax sensitivity was correlated with baseline BCL-2 expression. 4, 5 Herein, we present a CTCL patient with skin and blood involvement treated with daily venetoclax.